Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs
We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphom...
Gespeichert in:
| Veröffentlicht in: | Journal of Veterinary Medical Science 2017, Vol.79(7), pp.1225-1229 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1229 |
|---|---|
| container_issue | 7 |
| container_start_page | 1225 |
| container_title | Journal of Veterinary Medical Science |
| container_volume | 79 |
| creator | YAMAZAKI, Hiroki MIURA, Naoki LAI, Yu-Chang TAKAHASHI, Masashi GOTO-KOSHINO, Yuko YASUYUKI, Momoi NAKAICHI, Munekazu TSUJIMOTO, Hajime SETOGUCHI, Asuka ENDO, Yasuyuki |
| description | We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphoma. The clinical data showed that PDGFRα expression was higher in canine subjects with MDR T-cell lymphoma than in those with untreated T-cell lymphoma, and that c-KIT expression was greater in subjects with T-cell lymphoma than in those with B-cell lymphoma. TOC monotherapy was well tolerated without serious adverse effects, and two of the five subjects that received TOC exhibited partial responses. The data presented here could contribute to the assessment of TOC-based therapy for dogs with MDR or T-cell lymphoma. |
| doi_str_mv | 10.1292/jvms.16-0457 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5559368</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1907321123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c662t-3ff23aace22655ad371264d6d1a2ee502c2ca2cf3ddc03258fe2dd344a1a60023</originalsourceid><addsrcrecordid>eNpdkUFvFCEYhonR2G315tmQeKmJU-FjYJZLE21aNWmiBz0aQoHZYTMDKzBN9t_LZNeNeoGE7-EJLy9Cryi5oiDh_fZxyldUNKTl3RO0oqztmq5l8ilaEVnPO-DkDJ3nvCUEaCvkc3QGay6ho3KFft72vTMl49jjEo1LOvgHvBti3g26OHz5TY-jtl6_xVMMsQyV2O1xDHiax-Jtmjc4uexz0aHgcT_Vq5PGPmAbN_kFetbrMbuXx_0C_bi7_X7zubn_-unLzYf7xggBpWF9D0xr4wAE59qyjoJorbBUg3OcgAGjwfTMWkMY8HXvwFrWtppqUVOxC3R98O7mh8lZ40JJelS75Ced9ipqr_6dBD-oTXxUnHPJxLoKLo-CFH_NLhc1-WxcjR5cnLOiknQMKAVW0Tf_ods4p1DjKQAmBQAVC_XuQJkUc06uPz2GErX0ppbeFBVq6a3ir_8OcIL_FFWBjwdgW396406ATsWb0R1snVTdshytp6EZdFIusN_XXK4J</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2239622163</pqid></control><display><type>article</type><title>Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>YAMAZAKI, Hiroki ; MIURA, Naoki ; LAI, Yu-Chang ; TAKAHASHI, Masashi ; GOTO-KOSHINO, Yuko ; YASUYUKI, Momoi ; NAKAICHI, Munekazu ; TSUJIMOTO, Hajime ; SETOGUCHI, Asuka ; ENDO, Yasuyuki</creator><creatorcontrib>YAMAZAKI, Hiroki ; MIURA, Naoki ; LAI, Yu-Chang ; TAKAHASHI, Masashi ; GOTO-KOSHINO, Yuko ; YASUYUKI, Momoi ; NAKAICHI, Munekazu ; TSUJIMOTO, Hajime ; SETOGUCHI, Asuka ; ENDO, Yasuyuki</creatorcontrib><description>We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphoma. The clinical data showed that PDGFRα expression was higher in canine subjects with MDR T-cell lymphoma than in those with untreated T-cell lymphoma, and that c-KIT expression was greater in subjects with T-cell lymphoma than in those with B-cell lymphoma. TOC monotherapy was well tolerated without serious adverse effects, and two of the five subjects that received TOC exhibited partial responses. The data presented here could contribute to the assessment of TOC-based therapy for dogs with MDR or T-cell lymphoma.</description><identifier>ISSN: 0916-7250</identifier><identifier>EISSN: 1347-7439</identifier><identifier>DOI: 10.1292/jvms.16-0457</identifier><identifier>PMID: 28592719</identifier><language>eng</language><publisher>Japan: JAPANESE SOCIETY OF VETERINARY SCIENCE</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; B-cell lymphoma ; c-Kit protein ; Cell Line, Tumor ; dog ; Dog Diseases - drug therapy ; Dogs ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Female ; Gene expression ; Growth factors ; Indoles - therapeutic use ; Internal Medicine ; Lymphocytes B ; Lymphocytes T ; Lymphoma ; Lymphoma - drug therapy ; Lymphoma - veterinary ; Male ; Multidrug resistance ; Phosphates ; Platelet-derived growth factor ; Pyrroles - therapeutic use ; T-cell lymphoma ; toceranib phosphate ; Vascular endothelial growth factor ; Vascular endothelial growth factor receptor 2</subject><ispartof>Journal of Veterinary Medical Science, 2017, Vol.79(7), pp.1225-1229</ispartof><rights>2017 by the Japanese Society of Veterinary Science</rights><rights>Copyright Japan Science and Technology Agency Jul 2017</rights><rights>2017 The Japanese Society of Veterinary Science 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c662t-3ff23aace22655ad371264d6d1a2ee502c2ca2cf3ddc03258fe2dd344a1a60023</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559368/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559368/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28592719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YAMAZAKI, Hiroki</creatorcontrib><creatorcontrib>MIURA, Naoki</creatorcontrib><creatorcontrib>LAI, Yu-Chang</creatorcontrib><creatorcontrib>TAKAHASHI, Masashi</creatorcontrib><creatorcontrib>GOTO-KOSHINO, Yuko</creatorcontrib><creatorcontrib>YASUYUKI, Momoi</creatorcontrib><creatorcontrib>NAKAICHI, Munekazu</creatorcontrib><creatorcontrib>TSUJIMOTO, Hajime</creatorcontrib><creatorcontrib>SETOGUCHI, Asuka</creatorcontrib><creatorcontrib>ENDO, Yasuyuki</creatorcontrib><title>Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs</title><title>Journal of Veterinary Medical Science</title><addtitle>J. Vet. Med. Sci.</addtitle><description>We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphoma. The clinical data showed that PDGFRα expression was higher in canine subjects with MDR T-cell lymphoma than in those with untreated T-cell lymphoma, and that c-KIT expression was greater in subjects with T-cell lymphoma than in those with B-cell lymphoma. TOC monotherapy was well tolerated without serious adverse effects, and two of the five subjects that received TOC exhibited partial responses. The data presented here could contribute to the assessment of TOC-based therapy for dogs with MDR or T-cell lymphoma.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B-cell lymphoma</subject><subject>c-Kit protein</subject><subject>Cell Line, Tumor</subject><subject>dog</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Gene expression</subject><subject>Growth factors</subject><subject>Indoles - therapeutic use</subject><subject>Internal Medicine</subject><subject>Lymphocytes B</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma - drug therapy</subject><subject>Lymphoma - veterinary</subject><subject>Male</subject><subject>Multidrug resistance</subject><subject>Phosphates</subject><subject>Platelet-derived growth factor</subject><subject>Pyrroles - therapeutic use</subject><subject>T-cell lymphoma</subject><subject>toceranib phosphate</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular endothelial growth factor receptor 2</subject><issn>0916-7250</issn><issn>1347-7439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUFvFCEYhonR2G315tmQeKmJU-FjYJZLE21aNWmiBz0aQoHZYTMDKzBN9t_LZNeNeoGE7-EJLy9Cryi5oiDh_fZxyldUNKTl3RO0oqztmq5l8ilaEVnPO-DkDJ3nvCUEaCvkc3QGay6ho3KFft72vTMl49jjEo1LOvgHvBti3g26OHz5TY-jtl6_xVMMsQyV2O1xDHiax-Jtmjc4uexz0aHgcT_Vq5PGPmAbN_kFetbrMbuXx_0C_bi7_X7zubn_-unLzYf7xggBpWF9D0xr4wAE59qyjoJorbBUg3OcgAGjwfTMWkMY8HXvwFrWtppqUVOxC3R98O7mh8lZ40JJelS75Ced9ipqr_6dBD-oTXxUnHPJxLoKLo-CFH_NLhc1-WxcjR5cnLOiknQMKAVW0Tf_ods4p1DjKQAmBQAVC_XuQJkUc06uPz2GErX0ppbeFBVq6a3ir_8OcIL_FFWBjwdgW396406ATsWb0R1snVTdshytp6EZdFIusN_XXK4J</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>YAMAZAKI, Hiroki</creator><creator>MIURA, Naoki</creator><creator>LAI, Yu-Chang</creator><creator>TAKAHASHI, Masashi</creator><creator>GOTO-KOSHINO, Yuko</creator><creator>YASUYUKI, Momoi</creator><creator>NAKAICHI, Munekazu</creator><creator>TSUJIMOTO, Hajime</creator><creator>SETOGUCHI, Asuka</creator><creator>ENDO, Yasuyuki</creator><general>JAPANESE SOCIETY OF VETERINARY SCIENCE</general><general>Japan Science and Technology Agency</general><general>The Japanese Society of Veterinary Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2017</creationdate><title>Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs</title><author>YAMAZAKI, Hiroki ; MIURA, Naoki ; LAI, Yu-Chang ; TAKAHASHI, Masashi ; GOTO-KOSHINO, Yuko ; YASUYUKI, Momoi ; NAKAICHI, Munekazu ; TSUJIMOTO, Hajime ; SETOGUCHI, Asuka ; ENDO, Yasuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c662t-3ff23aace22655ad371264d6d1a2ee502c2ca2cf3ddc03258fe2dd344a1a60023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B-cell lymphoma</topic><topic>c-Kit protein</topic><topic>Cell Line, Tumor</topic><topic>dog</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Gene expression</topic><topic>Growth factors</topic><topic>Indoles - therapeutic use</topic><topic>Internal Medicine</topic><topic>Lymphocytes B</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma - drug therapy</topic><topic>Lymphoma - veterinary</topic><topic>Male</topic><topic>Multidrug resistance</topic><topic>Phosphates</topic><topic>Platelet-derived growth factor</topic><topic>Pyrroles - therapeutic use</topic><topic>T-cell lymphoma</topic><topic>toceranib phosphate</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular endothelial growth factor receptor 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YAMAZAKI, Hiroki</creatorcontrib><creatorcontrib>MIURA, Naoki</creatorcontrib><creatorcontrib>LAI, Yu-Chang</creatorcontrib><creatorcontrib>TAKAHASHI, Masashi</creatorcontrib><creatorcontrib>GOTO-KOSHINO, Yuko</creatorcontrib><creatorcontrib>YASUYUKI, Momoi</creatorcontrib><creatorcontrib>NAKAICHI, Munekazu</creatorcontrib><creatorcontrib>TSUJIMOTO, Hajime</creatorcontrib><creatorcontrib>SETOGUCHI, Asuka</creatorcontrib><creatorcontrib>ENDO, Yasuyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Veterinary Medical Science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YAMAZAKI, Hiroki</au><au>MIURA, Naoki</au><au>LAI, Yu-Chang</au><au>TAKAHASHI, Masashi</au><au>GOTO-KOSHINO, Yuko</au><au>YASUYUKI, Momoi</au><au>NAKAICHI, Munekazu</au><au>TSUJIMOTO, Hajime</au><au>SETOGUCHI, Asuka</au><au>ENDO, Yasuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs</atitle><jtitle>Journal of Veterinary Medical Science</jtitle><addtitle>J. Vet. Med. Sci.</addtitle><date>2017</date><risdate>2017</risdate><volume>79</volume><issue>7</issue><spage>1225</spage><epage>1229</epage><pages>1225-1229</pages><issn>0916-7250</issn><eissn>1347-7439</eissn><abstract>We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphoma. The clinical data showed that PDGFRα expression was higher in canine subjects with MDR T-cell lymphoma than in those with untreated T-cell lymphoma, and that c-KIT expression was greater in subjects with T-cell lymphoma than in those with B-cell lymphoma. TOC monotherapy was well tolerated without serious adverse effects, and two of the five subjects that received TOC exhibited partial responses. The data presented here could contribute to the assessment of TOC-based therapy for dogs with MDR or T-cell lymphoma.</abstract><cop>Japan</cop><pub>JAPANESE SOCIETY OF VETERINARY SCIENCE</pub><pmid>28592719</pmid><doi>10.1292/jvms.16-0457</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0916-7250 |
| ispartof | Journal of Veterinary Medical Science, 2017, Vol.79(7), pp.1225-1229 |
| issn | 0916-7250 1347-7439 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5559368 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Animals Antineoplastic Agents - therapeutic use B-cell lymphoma c-Kit protein Cell Line, Tumor dog Dog Diseases - drug therapy Dogs Drug Resistance, Multiple Drug Resistance, Neoplasm Female Gene expression Growth factors Indoles - therapeutic use Internal Medicine Lymphocytes B Lymphocytes T Lymphoma Lymphoma - drug therapy Lymphoma - veterinary Male Multidrug resistance Phosphates Platelet-derived growth factor Pyrroles - therapeutic use T-cell lymphoma toceranib phosphate Vascular endothelial growth factor Vascular endothelial growth factor receptor 2 |
| title | Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A23%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20toceranib%20phosphate%20(Palladia)%20monotherapy%20on%20multidrug%20resistant%20lymphoma%20in%20dogs&rft.jtitle=Journal%20of%20Veterinary%20Medical%20Science&rft.au=YAMAZAKI,%20Hiroki&rft.date=2017&rft.volume=79&rft.issue=7&rft.spage=1225&rft.epage=1229&rft.pages=1225-1229&rft.issn=0916-7250&rft.eissn=1347-7439&rft_id=info:doi/10.1292/jvms.16-0457&rft_dat=%3Cproquest_pubme%3E1907321123%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2239622163&rft_id=info:pmid/28592719&rfr_iscdi=true |